<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996420</url>
  </required_header>
  <id_info>
    <org_study_id>Emospin 2</org_study_id>
    <nct_id>NCT04996420</nct_id>
  </id_info>
  <brief_title>Goal Directed Fluid Therapy Versus Liberal Fluid Regimen in Primary Elective Hip Artrhoplasty</brief_title>
  <official_title>Goal Directed Fluid Management vs Liberal Fluid Regimen Based on Mean Arterial Pressure in Patients Undergoing Spinal Anesthesia for Primary Elective Hip Arthroplasty: a Randomized, Prospective, Controlled Study.&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing elective primary total hip replacement and spinal anesthesia may&#xD;
      encounter significant hemodynamic instability.&#xD;
&#xD;
      The study is a randomized controlled type and is aimed at comparing how perioperatory&#xD;
      hypotension and fluid regimen are managed using Clearsight non invasive monitoring system or&#xD;
      PAM monitoring.&#xD;
&#xD;
      The primary endpoint is to evaluate total duration of hypotension, defined as a MAP &lt; 65&#xD;
      mmHg, calculated during all the perioperatory time.&#xD;
&#xD;
      Fifty-eight patients, aged 50-80 years, with an American Society of Anaesthesiologists' (ASA)&#xD;
      score I, II and III were enrolled and split in two groups (Clearsight and control group).&#xD;
      Patients were monitored both with the EV1000 platform, the Clearsight finger-cuff and MAP&#xD;
      monitoring. Depending on the group, the fluid regimen was a goal directed fluid therapy or a&#xD;
      liberal fluid regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    change in surgical technique (lateral approach vs anterior approach for hip arthroplasty,&#xD;
    determining a change in patient intraoperative positioning)&#xD;
  </why_stopped>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Actual">November 22, 2020</completion_date>
  <primary_completion_date type="Actual">November 22, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total perioperative hypotension time defined by a mean arterial pressure &lt; 65mmHg, from arrival in the anesthesia induction room to resolution of spinal block in Recovery Room (i.e. up to 8 hours)</measure>
    <time_frame>from arrival in the anesthesia induction room to resolution of spinal block in Recovery Room</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Arthroplasty, Replacement, Hip</condition>
  <condition>Anesthesia, Spinal</condition>
  <condition>Hemodynamic Monitoring</condition>
  <condition>Crystalloid Solutions</condition>
  <arm_group>
    <arm_group_label>Clearsight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hemodynamic monitoring and goal directed fluid therapy guided by clearsight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>hemodynamic monitoring blinded and silenced, no goal directed fluid therapy. Fluid therapy based on clinical evaluation and mean arterial pressure by non-invasive monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clearsight non invasive hemodynamic monitoring</intervention_name>
    <description>Goal directed fluid therapy fuided by Clearsight monitoring</description>
    <arm_group_label>Clearsight</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 50-80 years&#xD;
&#xD;
          -  ASA I, II or III&#xD;
&#xD;
          -  primary elective hip arthroplasty&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  spinal anesthesia contraindications&#xD;
&#xD;
          -  periferical vasculopaty&#xD;
&#xD;
          -  other diseases which indicates better an invasive monitoring by radial artery&#xD;
             cannulation&#xD;
&#xD;
          -  atrial fibrillation&#xD;
&#xD;
          -  denial or inability to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Bonarelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Ortopedico Rizzoli</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IORizzoli</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Ortopedico Rizzoli</investigator_affiliation>
    <investigator_full_name>Daniela Ghisi</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

